Erratum: Non-adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: Results from a prospective multicentre study (Journal of Crohn's and Colitis DOI: 10.1093/ecco-jcc/jjw002);Non-adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: Results from a prospective multicentre study

Journal of Crohn's and Colitis

Volumn 10, Issue 5, 2016, Pages 549-555

  van der Have, Mike ^a   Oldenburg, Bas ^a   Kaptein, Ad A ^b   Jansen, Jeroen M ^c   Scheffer, Robert C H ^d   van Tuyl, Bas A ^e   van der Meulen de Jong, Andrea E ^b   Pierik, Marieke ^f   Siersema, Peter D ^a   van Oijen, Martijn G H ^a,g   Fidder, Herma H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e DEPARTMENT OF SURGERY   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Adherence; Illness perceptions; Inflammatory bowel disease; Medication beliefs; Predictors

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MESALAZINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CORTICOSTEROID THERAPY; CROHN DISEASE; DEMOGRAPHY; DISEASE DURATION; DRUG DOSE INTENSIFICATION; DRUG WITHDRAWAL; EMOTION; FEMALE; HOSPITALIZATION; HUMAN; INFLAMMATORY BOWEL DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; ULCERATIVE COLITIS; ADOLESCENT; AGED; CLINICAL TRIAL; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; PSYCHOLOGY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84982217584     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjy083     Document Type: Erratum

References (45)

1. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59.
2. Costa J, Magro F, Caldeira D, Alarcão J, Sousa R, Vaz-Carneiro A. Infliximab reduces hospitalisations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013;19:2098-110.
3. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalisation and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008;135:1493-9.
4. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-60.
5. Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG. Low rates of adherence for tumor necrosis factor-a inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol 2013;19:4344-50.
6. Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis 2013;19:1528-33.
7. Carter CT, Waters HC, Smith DB. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs. Adv Ther 2011;28:671-83.
8. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther 2009;26:936-46.
9. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
10. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
11. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002:CD000011.
12. Greenley RN, Kunz JH, Walter J, Hommel KA. Practical strategies for enhancing adherence to treatment regimen in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1534-45.
13. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One 2013;8:e80633.
14. Kucukarslan SN. A review of published studies of patients' illness perceptions and medication adherence: lessons learned and future directions. Res Social Adm Pharm 2012;8:371-82.
15. Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010;105:525-39.
16. Selinger CP, Eaden J, Jones DB, et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2199-206.
17. Horne R. Representations of medication and treatment: advances in theory and measurement In: Petrie KJ, Weinman JA (eds). Perceptions of Health and Illness: Current Research and Applications. London: Harwood Academic Press, 1997.
18. Leventhal H, Brissette I, Leventhal EA. The Common-Sense Model of selfregulation of health and illness. In: Cameron LD, Leventhal H (eds). The Self-Regulation of Health and Illness Behaviour. London: Routledge, 2003.
19. Stange EF, Travis SP, Vermeire S, et al.; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;55[Suppl 1]:i1-i15.
20. Stange EF, Travis SP, Vermeire S, et al.; European Crohn's and Colitis Organisation [ECCO]. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2:1-23.
21. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980;1:876.
22. Evertsz' FB, Hoeks CC, Nieuwkerk PT, et al. Development of the patient Harvey Bradshaw index and a comparison with a clinician-based Harvey Bradshaw index assessment of Crohn's disease activity. J Clin Gastroenterol 2013;47:850-6.
23. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998;43:29-32.
24. Bennebroek Evertsz' F, Nieuwkerk PT, Stokkers PC, et al. The patient simple clinical colitis activity index [P-SCCAI] can detect ulcerative colitis [UC] disease activity in remission: a comparison of the P-SCCAI with clinician-based SCCAI and biological markers. J Crohns Colitis 2013;7:890-900.
25. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res 2006;60:631-7.
26. Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24.
27. Horne R, Parham R, Driscoll R, Driscoll R, Robinson A. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2009;15:837-44.
28. Trindade AJ, Ehrlich A, Kornbluth A, Ullman TA. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis.2011;17:599-604.
29. Kane S, Becker B, Harmsen WS, Kurian A, Morisky DE, Zinsmeister AR. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol 2012;107:154-60.
30. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-8.
31. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011;33:987-95.
32. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a singlecentre cohort. Gut 2009;58:492-500.
33. Pouw MF, Krieckaert CL, Nurmohamed MT, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 2015;74:513-8.
34. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148: 132-09.
35. Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2015;13:522-30.e2.
36. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011;106:674-84.
37. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7.
38. Kane SV, Robinson A. Review article: understanding adherence to medication in ulcerative colitis innovative thinking and evolving concepts. Aliment Pharmacol Ther 2010;32:1051-8.
39. Long MD, Kappelman MD, Martin CF, et al. Development of an internet based cohort of patients with inflammatory bowel disease [CCFA partners]: methodology and initial results. Inflamm Bowel Dis 2012;18:2099-106.
40. Zugelj U, Zupancic M, Komidar L, Kenda R, Varda NM, Gregoric A. Selfreported adherence behavior in adolescent hypertensive patients: the role of illness representations and personality. J Pediatr Psychol 2010;35:1049-60.
41. Ross S, Walker A, MacLeod M. Patient compliance in hypertension: role of illness perceptions and treatment beliefs. J Hum Hypertens 2004;18:607-13.
42. Halm EA, Mora P, Leventhal H. No symptoms, no asthma: the acute episodic disease belief is associated with poor self-management among innercity adults with persistent asthma. Chest 2006;129:573-80.
43. Hagger MS, Orbell S. A meta-analytic review of the common sense model of illness representations. Psychol Health 2003;18:141-84.
44. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised, controlled trial. BMC Med Res Methodol 2007;7:30.
45. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev.2008;16:CD000011.